Despite advances in surgery, radiotherapy, chemotherapy and targeted treatments, resistance remains a major obstacle in nervous system (NS) tumours. Treatment failure reflects not only individual oncogenic alterations but also adaptive regulatory networks that enable tumour cells to survive therapeutic stress, maintain plasticity and adopt therapy-tolerant phenotypes. Within these networks, long non-coding RNAs (lncRNAs) have emerged as potential therapeutic targets because of their spatiotemporal expression patterns, context-dependent functions and ability to coordinate gene-expression programmes. Advances in RNA therapeutics provide tools to exploit these properties by targeting disease-associated transcripts and RNA-dependent interactions that are difficult to address with conventional small molecules or antibodies. Studies in NS tumour models have implicated lncRNAs as determinants of therapeutic responses, including DNA repair, apoptotic thresholds, stem-like states, mesenchymal-like plasticity, invasion, metabolic adaptation and stress responses, as well as intercellular communication within the tumour microenvironment. Targeting oncogenic lncRNAs may weaken resistance programmes and enhance the activity of partner treatments, providing a rationale for combinations that could maintain antitumour efficacy at lower drug doses. In this Review, we discuss the rationale for targeting lncRNAs to influence therapeutic response in NS tumours. The evidence is concentrated in gliomas, particularly glioblastoma, with additional studies in other entities. We summarise preclinical evidence for combining lncRNA-directed interventions with chemotherapy or radiotherapy, distinguishing changes in treatment sensitivity and resistance from quantitatively demonstrated synergy. We discuss targeting strategies, including antisense oligonucleotides, siRNAs and interaction-disrupting approaches, and consider translational challenges related to target selection, context-dependent biology, tumour heterogeneity, intracellular accessibility, delivery to tumours and potential toxicity to normal tissues. Collectively, these findings support lncRNAs as potentially actionable regulatory nodes and provide a foundation for developing more effective and better-tolerated combinatorial strategies in NS tumours.

Targeting Long Non-Coding RNAs to Improve Therapeutic Response in Nervous System Tumours / Tollis, P., Belvedere, A., Grandioso, A., Ballarino, M., Laneve, P.. - (2026). [10.20944/preprints202611.1675.v1]

Targeting Long Non-Coding RNAs to Improve Therapeutic Response in Nervous System Tumours

Paolo Tollis
Co-primo
;
Alessandro Belvedere
Co-primo
;
Alessia Grandioso;Monica Ballarino
;
Pietro Laneve
2026

Abstract

Despite advances in surgery, radiotherapy, chemotherapy and targeted treatments, resistance remains a major obstacle in nervous system (NS) tumours. Treatment failure reflects not only individual oncogenic alterations but also adaptive regulatory networks that enable tumour cells to survive therapeutic stress, maintain plasticity and adopt therapy-tolerant phenotypes. Within these networks, long non-coding RNAs (lncRNAs) have emerged as potential therapeutic targets because of their spatiotemporal expression patterns, context-dependent functions and ability to coordinate gene-expression programmes. Advances in RNA therapeutics provide tools to exploit these properties by targeting disease-associated transcripts and RNA-dependent interactions that are difficult to address with conventional small molecules or antibodies. Studies in NS tumour models have implicated lncRNAs as determinants of therapeutic responses, including DNA repair, apoptotic thresholds, stem-like states, mesenchymal-like plasticity, invasion, metabolic adaptation and stress responses, as well as intercellular communication within the tumour microenvironment. Targeting oncogenic lncRNAs may weaken resistance programmes and enhance the activity of partner treatments, providing a rationale for combinations that could maintain antitumour efficacy at lower drug doses. In this Review, we discuss the rationale for targeting lncRNAs to influence therapeutic response in NS tumours. The evidence is concentrated in gliomas, particularly glioblastoma, with additional studies in other entities. We summarise preclinical evidence for combining lncRNA-directed interventions with chemotherapy or radiotherapy, distinguishing changes in treatment sensitivity and resistance from quantitatively demonstrated synergy. We discuss targeting strategies, including antisense oligonucleotides, siRNAs and interaction-disrupting approaches, and consider translational challenges related to target selection, context-dependent biology, tumour heterogeneity, intracellular accessibility, delivery to tumours and potential toxicity to normal tissues. Collectively, these findings support lncRNAs as potentially actionable regulatory nodes and provide a foundation for developing more effective and better-tolerated combinatorial strategies in NS tumours.
2026
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1782037
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact